Metropolitan Life Insurance CO Kala Pharmaceuticals, Inc. Transaction History

Metropolitan Life Insurance CO

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$6.24 - $9.58 $68,796 - $105,619	-11,025 Closed	0 $0
Q4 2020 Jun 22, 2023	BUY	$6.28 - $8.79 $69,237 - $96,909	11,025 New	11,025 $74,000
Q4 2020 Mar 30, 2023	SELL	$6.28 - $8.79 $11,837 - $16,569	-1,885 Reduced 14.6%	11,025 $74,000
Q4 2020 Feb 16, 2021	SELL	$6.28 - $8.79 $11,837 - $16,569	-1,885 Reduced 14.6%	11,025 $75,000
Q3 2020 Jun 26, 2023	BUY	$7.5 - $11.11 $96,825 - $143,430	12,910 New	12,910 $96,000

Q3 2020 Mar 30, 2023	SELL	$7.5 - $11.11 $487 - $722	-65 Reduced 0.5%	12,910 $96,000
Q3 2020 Nov 13, 2020	SELL	$7.5 - $11.11 $487 - $722	-65 Reduced 0.5%	12,910 $97,000
Q2 2020 Jun 26, 2023	BUY	$8.33 - $13.79 $108,081 - $178,925	12,975 New	12,975 $136,000
Q2 2020 Mar 30, 2023	BUY	$8.33 - $13.79 $36,143 - $59,834	4,339 Added 50.24%	12,975 $136,000
Q2 2020 Aug 14, 2020	BUY	$8.33 - $13.79 $36,143 - $59,834	4,339 Added 50.24%	12,975 $136,000
Q1 2020 Jul 12, 2023	BUY	$3.83 - $8.79 $33,075 - $75,910	8,636 New	8,636 $75,000
Q1 2020 Mar 30, 2023	BUY	$3.83 - $8.79 $33,075 - $75,910	8,636 New	8,636 $75,000
Q1 2020 May 15, 2020	BUY	$3.83 - $8.79 $33,075 - $75,910	8,636 New	8,636 $76,000
Q2 2018 Aug 15, 2018	SELL	$13.3 - $17.49 $70,263 - $92,399	-5,283 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$12.26 - $18.98 $64,769 - $100,271	5,283 New	5,283 $0
Q4 2017 Feb 15, 2018	SELL	$13.68 - $23.17 $154,775 - $262,145	-11,314 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$19.86 - $26.53 $224,696 - $300,160	11,314	11,314 $258,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $10.4M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.